KURA

Kura Oncology Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 2/10
  • Momentum↓ 4/10
Kura Oncology sales and earnings growth
KURA Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -5.08%
  • FCF Y/Y↑ 149.11%
Kura Oncology gross and profit margin trends
KURA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -208.50%
  • ROIC↓ -41.40%
Kura Oncology net debt vs free cash flow
KURA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -135.8

Kura Oncology stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗